ArcChem Research

CNS Research & Development

Developing next-generation compounds targeting wakefulness, affect-salience, and stress resilience.

Lucerin Program

Lucerin is a novel chiral DRI (dopamine reuptake inhibitor) — a wakefulness and affect-salience modulator designed to convert alertness into usable life energy through selective receptor engagement.

Core thesis: Existing wake-promoting agents leave users awake yet disengaged. Lucerin addresses this gap with sustained engagement, restored motivation, and stress resilience.

Contact

Research inquiries: research@arcchem.com